What is Leede Financial's Estimate for THTX FY2025 Earnings?

Theratechnologies Inc. (NASDAQ:THTX - Free Report) - Equities researchers at Leede Financial dropped their FY2025 earnings per share (EPS) estimates for shares of Theratechnologies in a report released on Wednesday, February 26th. Leede Financial analyst D. Loe now expects that the company will post earnings per share of $0.06 for the year, down from their prior forecast of $0.07. The consensus estimate for Theratechnologies' current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies' FY2026 earnings at $0.15 EPS.

Separately, Research Capitl raised shares of Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.

Theratechnologies Stock Performance

NASDAQ THTX traded up $0.03 during trading hours on Thursday, reaching $1.65. The stock had a trading volume of 71,740 shares, compared to its average volume of 117,445. Theratechnologies has a 52-week low of $1.08 and a 52-week high of $2.18. The stock has a market cap of $75.87 million, a P/E ratio of -16.50 and a beta of 1.26. The stock has a fifty day moving average of $1.74 and a 200 day moving average of $1.45.

Institutional Investors Weigh In On Theratechnologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its stake in shares of Theratechnologies by 1,416.7% in the fourth quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock worth $30,000 after buying an additional 15,400 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Theratechnologies in the fourth quarter valued at approximately $36,000. Raymond James Financial Inc. purchased a new stake in Theratechnologies in the 4th quarter worth approximately $27,000. JPMorgan Chase & Co. acquired a new stake in shares of Theratechnologies during the 4th quarter worth approximately $33,000. Finally, Hillsdale Investment Management Inc. acquired a new stake in shares of Theratechnologies during the 4th quarter worth approximately $108,000.

Remove Ads

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.